Top 5 Cheapest Companies To Watch For 2016

Related NR Benzinga's Top Upgrades Credit Suisse Upgrades 3 Names In Oilfield Services & Equipment, Downgrades 6

Capital One has upgraded Newpark Resources Inc (NYSE: NR) to Overweight from Equal Weight on improved fundamentals, primarily the removal of balance sheet concerns.

“We moved the name higher in our relative bias index a couple of weeks ago given the aforementioned removal of balance sheet concerns and that it continues to slot in the top tier of our group in terms of growth potential looking into ’18 (combination of NAm onshore recovery off the bottom, continued EMEA growth, and assumed GoM deepwater share gains kicking in),” Joseph Gibney wrote in a note.

Top 5 Cheapest Companies To Watch For 2016: Inter Parfums, Inc.(IPAR)

 

Inter Parfums, Inc., together with its subsidiaries, manufactures, markets, and distributes a range of fragrances and fragrance related products worldwide. It offers its fragrance and cosmetic products under the Balmain, Boucheron, Jimmy Choo, Karl Lagerfeld, Lanvin, Montblanc, Paul Smith, S.T. Dupont, Repetto, Van Cleef & Arpels, Abercrombie & Fitch, Agent Provocateur, Rochas, Anna Sui, Banana Republic, bebe, Coach, Dunhill, French Connection, Gap, Hollister, Oscar de la Renta, and Shanghai Tang brands. It markets and sells its products to department stores, perfumeries, specialty retailers, mass market retailers, supermarkets, domestic and international wholesalers, and distributors. The company was formerly known as Jean Philippe Fragrances, Inc. and changed its name to Inter Parfums, Inc. in July 1999. Inter Parfums, Inc. was founded in 1985 and is headquartered in New York, New York.

Advisors’ Opinion:

  • [By Monica Gerson]

    Inter Parfums, Inc. (NASDAQ: IPAR) is estimated to post its quarterly earnings at $0.31 per share on revenue of $110.58 million.

    Norwegian Cruise Line Holdings Ltd (NASDAQ: NCLH) is expected to report its quarterly earnings at $0.37 per share on revenue of $1.10 billion.

Top 5 Cheapest Companies To Watch For 2016: Intrepid Potash, Inc(IPI)

 

Intrepid Potash, Inc. engages in the extraction, production, and sale of potassium containing products in the United States. It produces muriate of potash and langbeinite, a low-chloride potassium fertilizer that contains sulfate and magnesium. The company also offers salt, magnesium chloride, and metal recovery salts. It serves agricultural, industrial, and animal feed markets. The company was incorporated in 2007 and is based in Denver, Colorado.

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Gains are being seen elsewhere as well, except in shares of The Mosaic Company (NYSE: MOS). AgriumInc. (NYSE: AGU) was up almost 3% at $91.95 in late Monday trading, although this one held up much better in the destructive news phase when the alarming news roiled these stocks. The big winner is Intrepid Potash, Inc. (NYSE: IPI), with a gain of 7% to $16.20 in late-Monday trading.

Top 10 Healthcare Technology Stocks To Own Right Now: CytRx Corporation(CYTR)

CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics, specializing in oncology. Its drug development pipeline includes INNO-206, which is in Phase II clinical trials for the treatment of soft tissue sarcomas and is in Phase Ib/2 clinical trials for the treatment of solid tumors; and tamibarotene that is in Phase II clinical trials for the treatment of non-small-cell lung cancer and acute promyelocytic leukemia. The company also develops Bafetinib, which is in Phase II clinical trials for the treatment of B-cell chronic lymphocytic leukemia and advanced prostate cancer, as well as in pharmacokinetic clinical trial for brain cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Advisors’ Opinion:

  • [By Roberto Pedone]

    Another under-$10 biotechnology player that’s starting to trend within range of triggering a major breakout trade is CytRx (CYTR), which has an oncology pipeline that includes two programs in clinical development for cancer indications: aldoxorubicin and tamibarotene. This stock has been moving to the upside during the last three months, with shares up by 21%.

    If you take a look at the chart for CytRx, you’ll notice that this stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $2.27 on the downside and $2.68 on the upside. That consolidation pattern has occurred right above this stock’s 50-day and 200-day moving averages. Shares of CYTR have now started to break out above some near-term overhead resistance at $2.49 a share. That move is quickly pushing CYTR within range of triggering an even bigger breakout trade above the upper-end of its recent sideways trading chart pattern.

    Market players should now look for long-biased trades in CYTR if it manages to break out above some near-term overhead resistance levels at $2.68 to $2.80 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 154,838 shares. If that breakout triggers soon, then CYTR will set up to re-test or possibly take out its next major overhead resistance levels at $3.20 to $4 a share.

    Traders can look to buy CYTR off any weakness to anticipate that breakout and simply use a stop that sits right below its 200-day at $2.33 a share or below more support at $2.27 a share. One can also buy CYTR off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 5 Cheapest Companies To Watch For 2016: Portola Pharmaceuticals, Inc.(PTLA)

 

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III clinical trial for venous thromboembolism prophylaxis in acute medically ill patients in-hospital and post discharge. The companys other lead development candidate, Andexanet alfa, a recombinant protein that is in Phase III registration studies designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. It has collaboration agreements with Biogen Idec Inc.; Bristol-Myers Squibb Company; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Lees Pharmaceutical (HK) Ltd. The company is also developing Cerdulatinib, which is in Phase I/IIa proof-of-concept study, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases enzymes, which regulate signaling pathways, as well as for hematologic, or blood, cancers, and inflammatory disorders. In addition, it is involved in the development of PRT2607, a selective Syk inhibitor. Portola Pharmaceuticals, Inc. has a collaboration with Bristol-Myers Squibb and Pfizer Inc. to develop and commercialize apixaban, an oral anticoagulant. The company was founded in 2003 and is headquartered in South San Francisco, California.

Advisors’ Opinion:

  • [By Lisa Levin]

    Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares dropped 30 percent to $20.08 after announcing Phase III Betrixaban results.

    Shares of Spark Energy Inc (NASDAQ: SPKE) were down 14 percent to $20.96. Spark Energy reported Q4 GAAP EPS of $(0.01) and adjusted EBITDA of $16.3 million.

Top 5 Cheapest Companies To Watch For 2016: National Grid Transco, PLC(NGG)

National Grid plc, incorporated on July 11, 2000, is an electricity and gas utility company focused on transmission and distribution activities in electricity and gas in both the United Kingdom and the United States. The Company’s segments include UK Electricity Transmission, which is engaged in high voltage electricity transmission networks in Great Britain; UK Gas Transmission, which is the gas transmission network in Great Britain and UK liquefied natural gas (LNG) storage activities; UK Gas Distribution, which includes approximately four of the eight regional networks of Great Britain’s gas distribution system, and US Regulated, which includes gas distribution networks, electricity distribution networks and high voltage electricity transmission networks in New York, and New England and electricity generation facilities in New York. Its other activities relate to non-regulated businesses and other commercial operations not included within the above segments, including t he United Kingdom gas metering activities; the Great Britain-France Interconnector; the United Kingdom property management; a United Kingdom LNG import terminal (National Grid Grain LNG Limited); the United States LNG operations; the United States unregulated transmission pipelines; together with corporate activities.

UK Electricity Transmission

The Company owns and operates the electricity transmission network in England and Wales, with day-to-day responsibility for balancing supply and demand. The Company operates but do not own the Scottish networks. Its networks comprise approximately 7,200 kilometers (over 4,470 miles) of overhead line, approximately 1,500 kilometers (over 930 miles) of underground cable and approximately 340 substations.

UK Gas Transmission

The Company owns and operates the gas national transmission system in Great Britain, with day-to-day responsibility for balancing supply and demand. Its network co mprises approximately 7,660 kilometers (over 4,760 miles) of! high pressure pipe and approximately 20 compressor stations. The gas throughput across the system is over 80 billion cubic meters.

UK Gas Distribution

The Company owns and operates approximately four gas distribution networks comprising over 131,000 kilometers (over 81,400 miles) of pipeline. The Company transports gas from the national transmission system to approximately 10.9 million consumers on behalf of approximately 40 shippers.

US Regulated

The Company jointly owns and operates transmission facilities across upstate New York, Massachusetts, New Hampshire, Rhode Island and Vermont. It owns and operates electricity distribution networks in upstate New York, Massachusetts and Rhode Island. The assets it operates include over 170 kilometers (approximately 110 miles) of underground cable, over 490 transmission substations and approximately 690 distribution substations. It owns and operates gas distribution networks acros s the northeastern United States, located in upstate New York, New York City, Long Island, Massachusetts and Rhode Island. The Company forecasts, plans for and procures over 20 billion standard cubic meters of gas each year.

Advisors’ Opinion:

  • [By Paul R. La Monica]

    And the infrastructure fund has stakes in cell phone tower owners Crown Castle (CCI) and SBA Communications (SBAC), as well as giant British gas and electric utility National Grid (NGG).